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PIN27
COST-EFFECTIVENESS OF CEFEPIME VERSUS
CEFOTAXIME WHEN ADDED TO
METRONIDAZOLE IN COMPLICATED
INTRAABDOMINAL INFECTIONS
Salas M1, Caro J1, Molinar F2
1Caro Research Institute, Concord, MA, USA; 2Intensive Care
Unit, Medical Center “La Raza”, Mexico City, Mexico
OBJECTIVES: Intraabdominal infections, with their high
morbidity and mortality, represent an immense treatment
challenge because multiple microorganisms are involved.
The addition of cefepime to metronidazole has been
shown to be effective but the cost of the drug is high.
Therefore, the objective of this study was to assess the
cost-effectiveness of this combination compared to cefo-
taxime-metronidazole from the perspective of the third-
party payer. METHODS: Data were obtained on the
resources consumed by 60 adults with intraabdominal
infection enrolled in a randomized trial carried out in the
Intensive Care Unit, Hospital of Specialties “La Raza”,
Mexico City comparing cefepime to cefotaxime, both in
addition to metronidazole. Clinical cure, improvement or
failure, was determined according to presence of symp-
toms while bacteriological cure depended on absence of
the initial microorganisms. For the economic study, data
on length of stay (LOS); use of special care units, labo-
ratory tests, radiology, nuclear medicine or other special
studies; number and type of surgeries as well as duration
of antimicrobial treatment were collected. Information
was extracted from patient charts and case report forms.
Unit costs were obtained from the hospital’s Finance
Department and are reported in 2001 US dollars (1 USD
= 10 MEX). RESULTS: There were no statistically sig-
niﬁcant differences between groups in age, gender,
number and type of diagnoses or severity of disease.
Staphylococcus aureus, Streptococcus spp, Escherichia
coli, Enterococcus spp and Pseudomona aeuruginosa
were most frequently isolated. There were no statisti-
cally signiﬁcant differences in the number and type of
tests. Clinical and bacteriologic efﬁcacy were similar 
between groups. However, patients receiving cefepime-
metronidazole had shorter LOS than patients receiving
cefotaxime-metronidazole (mean 21 days versus 27 days,
respectively) and thus lower total hospitalization costs
(mean $18,974 for cefepime-metronidazole vs. $20,092
for cefotaxime-metronidazole). Including the cost of the
drugs, the difference is reduced to $503 in favor of
cefepime-metronidazole. CONCLUSIONS: The combi-
nation of cefepime with metronidazole reduces average
total costs resulting in economic dominance over 
cefotaxime.
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ESTIMATED COST SAVINGS OF
DISCONTINUING SECONDARY PROPHYLAXIS
FOR OPPORTUNISTIC INFECTIONS AFTER
IMMUNOLOGICAL RECONSTITUTION 
WITH HAART
Becker RV, Gams E, Shakur IM
Ovation Research Group, Highland Park, IL, USA
OBJECTIVE: Three studies presented at the XIV Inter-
national AIDS conference in Barcelona, Spain give sup-
port to the discontinuation of secondary prophylaxis (SP)
of cryptocycoccal meningitis (CM), mycobacterium
avium (MAC), and disseminated histoplamosis (DH)
after immunological reconstitution with HAART. Our
objective was to estimate potential cost savings of with-
drawing secondary prophylaxis. METHODS: Three sep-
arate analyses were performed, one for each opportunistic
infection (OI) analyzed and were each comprised of 100
HIV-infected patients who were assumed to be naïve for
antiretroviral therapy and previously diagnosed with one
of the given OI’s. As in the prophylaxis studies, we
assumed that all patients were receiving HAART and 
secondary prophylaxis for six months. Clinical outcomes
following six months were taken from the prophy-
laxis studies and previously published HAART studies.
HAART and SP drug costs (2002 U.S. AWP) from the
payer perspective were determined for the period follow-
ing 6 months of HAART treatment through the duration
of each given prophylaxis-study time frame (11 months
for CM, 12 months for MAC, and 16 months for DH).
The number of patients in the cohort who could poten-
tially discontinue SP was calculated as was their per-
patient costs. Similar estimations were made for patients
who could not discontinue (including HAART non-
responders). Discounting was not performed due to the
short analytical timeframe. RESULTS: In the CM cohort,
42 patients discontinued SP at a monthly cost of
$1052.31 per patient versus $1449.61 for the remaining
76 patients not discontinuing (27.4% savings per dis-
continuation). In the MAC cohort, 24 patients discontin-
ued SP at a cost of $1052.31 per patient versus $1463.57
for the remainder (28.1% savings), and $1052.31 per
patient in the DH cohort where all patients discontinued
(30.7% savings). CONCLUSION: Given that discontinue
secondary prophylaxis is considered safe after immuno-
logical reconstitution with HAART, the potential cost
savings can be substantial.
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PHARMACOECONOMIC EVALUATION OF
ANTIMICROBIAL AGENTS IN THE TREATMENT
OF SEXUALLY TRANSMITTED DISEASES IN
LAGOS UNIVERSITY TEACHING HOSPITAL
Suleiman IA,Tayo F
College of Medicine, University of Lagos, Lagos, Nigeria
Increasing awareness of the utmost need for the limited
resources to be used more efﬁciently has called for eco-
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nomic evaluation of drug therapy. OBJECTIVES: This
was to assess the cost effectiveness of some antimicrobial
agents used in the treatment of sexually transmitted dis-
eases (STD). These include doxycycline versus tetracy-
cline for chlamydial infection, benzathine penicillin versus
procaine penicillin for syphilis, and ceftriaxone versus
spectinomycin for gonorrhoea. The choices were based on
standard treatment guidelines and observed prescrip-
tions. METHODS: Cost Effectiveness Analysis was used. 
The prescribed/dispensed prescriptions in STD clinic
between 1997 and 1999 were reviewed retrospectively.
Relevant information such as diagnosis, prescribed/
dispensed drugs, dosage, duration of therapy, laboratory
results, physician’s remarks among others were obtained
from patient case-notes and dispensed prescriptions. In
conjunction with these, time and motion studies and stan-
dard cost accounting technique were used. The cost per
deﬁned daily dose (DDD) and the cost of therapy for each
agent were calculated. The cost components include over-
head costs, and cost of drug/disposables acquisition. The
literature was reviewed for positive and negative conse-
quences of the considered therapeutic options. Improve-
ments in signs and symptoms as well as eradication of the
implicated organisms are the outcome measures. Decision
table was used in the effectiveness rating. These were
compared using chi square analysis. RESULTS: The
results showed that doxycycline, benzathine penicillin
and ceftriaxone were more effective than their respective
counterparts in the treatment of stated infections. For
example, doxycycline was N0.92 per unit effective while
tetracycline was N1.82 per unit effective. Tetracycline is
still widely used in the country. Alteration of some vari-
ables (cost and effectiveness rating) in favour of less cost
effective option did not change the conclusion conﬁrming
that doxycycline is truly more cost effective. CONCLU-
SION: It is concluded that tetracycline should no longer
be used except when doxycycline is not available. This
equally applies to benzathine penicillin and ceftriaxone
compared to their counterparts. However patients pecu-
liarities and contraindications need to be considered at all
times.
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HOSPITALIZATION EXPENDITURE OF
STREPTOCOCCUS PYOGENES-ASSOCIATED
CELLULITIS IN THE UNITED STATES
Liu Z1, Paramore C2, Ciesla G2, Shulman S3, Ciuryla V1
1Wyeth Research, Philadelphia, PA, USA; 2MEDTAP
International, Bethesda, MD, USA; 3Northwestern University,
Evanston, IL, USA
OBJECTIVE: To determine the impact of Streptococcus
pyogenes (group A streptococcus, GAS) associated cel-
lulitis on hospital expenditure in the United States.
METHODS: This study analyzed data from the Health-
care Cost and Utilization Project (2000) funded by the
Agency for Healthcare Research and Quality. Hospital-
izations due to cellulitis were identiﬁed using ICD-9 codes
681–682 as principal diagnoses. We assumed that
30–50% of cellulitis-related hospitalizations were caused
by GAS. RESULTS: In 2000, there were approximately
110,000–183,000 hospitalizations due to GAS-associated
cellulitis. Adults aged 18–64 years accounted for 56% of
the hospitalizations, followed by the elderly (65 years 
and older, 36%) and children (<18 years, 8%). The most
common comorbid conditions associated with cellulitis
were hypertension (28%), diabetes mellitus (13%) and
congestive heart failure (10%). The mean and median
length of hospital stay for cellulitis were about ﬁve and
four days, respectively. Total annual hospitalization
charges for GAS-associated cellulitis were estimated at
$1.2–2.0 billion in year 2002 US dollars. Average charge
per hospital stay was about $10,500. CONCLUSIONS:
GAS-associated cellulitis represents a signiﬁcant eco-
nomic burden in the US. Total annual hospitalization
charges estimated for GAS-associated cellulitis are signif-
icantly higher than the recent estimate by the Institute of
Medicine (Vaccines for the 21st Century, A Tool for Deci-
sionmaking, 2000) for all GAS-associated hospitaliza-
tions (<$100 million).
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THE COST-EFFECTIVENESS OF
PEGINTERFERON ALFA-2A (40KD) (PEGASYS)
PLUS RIBAVIRIN (COPEGUS) VS. INTERFERON
ALFA-2B PLUS RIBAVIRIN FOR CHRONIC
HEPATITIS C (CHC)
Sullivan SD1, Green J2, Patel KK2, Craxi A3,Alberti A4,
Giuliani G5, De Carli C5
1University of Washington, Seattle, WA, USA; 2Hoffmann-La
Roche Inc, Nutley, NJ, USA; 3University of Palermo, Palermo,
Italy; 4Universita degli Studi di Padova, Padova, Italy;
5Roche Milan, Monza (MI), Italy
OBJECTIVES: Peginterferon alfa-2a (40KD)/ribavirin
(PEG) has been shown to produce a higher rate of sus-
tained virological response (SVR) than non-pegylated
combination therapy (non-PEG) in CHC, but the cost-
effectiveness of this improved efﬁcacy has not been
assessed. METHODS: We used a Markov model of
disease progression in which the cohorts of hepatitis C
virus (HCV) patients received PEG or non-PEG for either
48 or 24 weeks depending on genotype and liver histol-
ogy and were followed for their expected lifetime. The
reference patient was a 45-year-old male with CHC
without cirrhosis. The SVRs to PEG and non-PEG were
46% and 36% for HCV genotype 1 and 76% and 61%
for non-1, respectively. Quality of life and costs for each
health state were based on literature and on Italian treat-
ment patterns. Costs in 2002 Euros and beneﬁts were 
discounted at 3%. RESULTS: In HCV genotype 1, PEG
increases life expectancy (LY) by 0.78 years and quality-
adjusted life expectancy (QALY) by 0.67 years compared
to non-PEG. The incremental cost per QALY gained is
12,026 Euros. In HCV non-1 genotype patients, PEG
increases LY by 1.17 and QALY by 1.01 years in com-
